Related Experiment Video

Updated: Aug 6, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Treatment of hypertrophic cardiomyopathy with coenzyme Q10

P H Langsjoen1, A Langsjoen, R Willis

  • 1Langsjoen Clinic, Tyler, TX 75701, USA.

Molecular Aspects of Medicine
|January 1, 1997
PubMed

Insights

Coenzyme Q10 (CoQ10) supplementation significantly reduced left ventricular wall thickness in hypertrophic cardiomyopathy (HCM) patients. This treatment also improved patient symptoms and reduced obstruction in one case.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is characterized by severe left ventricular thickening and diastolic dysfunction.
  • Previous studies suggested coenzyme Q10 (CoQ10) improves diastolic function in hypertensive heart disease.
  • This led to investigating CoQ10's efficacy in HCM patients.

Purpose of the Study:

  • To evaluate the therapeutic effect of coenzyme Q10 (CoQ10) on left ventricular wall thickness and diastolic function in patients with hypertrophic cardiomyopathy (HCM).

Main Methods:

  • Seven HCM patients (six non-obstructive, one obstructive) received an average of 200 mg/day of CoQ10.
  • Whole blood CoQ10 levels averaged 2.9 micrograms/ml.
  • Echocardiograms were performed at baseline and after 3+ months of treatment.

Main Results:

  • Significant reductions in mean interventricular septal thickness (24%) and posterior wall thickness (26%) were observed (P < 0.002 and P < 0.005, respectively).
  • Patients reported improved fatigue and dyspnea with no adverse effects.
  • The single obstructive patient experienced a decrease in resting pressure gradient from 70 mmHg to 30 mmHg.

Conclusions:

  • Coenzyme Q10 (CoQ10) treatment demonstrated significant efficacy in reducing left ventricular hypertrophy in HCM patients.
  • CoQ10 improved clinical symptoms and showed potential in managing obstructive HCM.
  • Further research is warranted to confirm these findings and explore CoQ10's role in HCM management.

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs07:24

A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs

Published on: March 13, 2026

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...